Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Data on the efficacy and safety of interferon (IFN)-α for the treatment of essential
thrombocythemia (ET) and polycythemia vera (PV) are inconsistent. We conducted a …

Background There is no evidence that phlebotomy alone is sufficient to steadily maintain
haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to …

We report the clinical presentation and risk factors for survival in 175 patients with
myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and …

Interferon-alpha (rIFNα) is the only disease-modifying treatment for polycythemia vera (PV),
but whether or not it prolongs survival is unknown. This large single center retrospective …

We aimed to study the prognostic impact of the mutational landscape in primary and
secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from …

Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …

Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN)
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …